| Literature DB >> 24884656 |
Jean Pastré, Anne Prévotat, Catherine Tardif, Carole Langlois, Alain Duhamel, Benoit Wallaert1.
Abstract
BACKGROUND: Adult patients with cystic fibrosis (CF) frequently have reduced exercise tolerance, which is multifactorial but mainly due to bronchial obstruction. The aim of this retrospective analysis was to determine the mechanisms responsible for exercise intolerance in patients with mild-to-moderate or severe disease.Entities:
Mesh:
Year: 2014 PMID: 24884656 PMCID: PMC4011768 DOI: 10.1186/1471-2466-14-74
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Demographic and clinical characteristics of the CF patients
| ∆F 508 homozygous mutationa | 31/79 (40%) |
| Smokera | 10/102 (10%) |
| Oxygen supplementationa | 11/95 (11%) |
| ABPAa | 33/95 (35%) |
| Exocrine pancreatic insufficiencya | 78/102 (76%) |
| Diabetesa | 21/102 (21%) |
| Nasal polyposisa | 25/94 (27%) |
| BMI, kg/m2b | 20 (20 ± 3) |
| Lean body mass, kgb | 45 (48 ± 9) |
| 63/99 (63%) | |
| 36/99 (36%) | |
| 4/99 (4%) | |
| Blood leukocytes, 1012/mm3b | 9 (9.7 ± 3.8) |
| Blood polymorphonuclear neutrophils, 1012/mm3b | 6 (6.4 ± 3.3) |
| CRP, mg/Lb | 5.5 (15 ± 30) |
| Serum albumin, g/Lb | 42 (42 ± 4) |
ABPA = allergic bronchopulmonary aspergillosis; BMI = body mass index; CRP = C-reactive protein.
Qualitative variables are given as frequency and percentage.
aResults are expressed as number (percentage) of patients.
bResults are expressed as median values (mean ± SD).
Resting pulmonary function tests in CF patients classified according to FEV
| FEV1 | | < 50% | ≥ 50% |
| FEV1a | 60 ± 28 | 35 ± 9b | 82 ± 18 |
| FVCa | 75 ± 24 | 56 ± 14b | 93 ± 16 |
| FEV1/FVC | 65 ± 15 | 54 ± 11b | 75 ± 10 |
| RVa | 176 ± 65 | 220 ± 50b | 135 ± 48 |
| DLCOa | 68 ± 18 | 56 ± 13b | 78 ± 14 |
| PaO2, mm Hg | 80 ± 14 | 71 ± 10b | 87 ± 12 |
| PaCO2, mm Hg | 38 ± 4 | 38 ± 5 | 37 ± 4 |
| P(A-a)O2, mm Hg | 29 ± 13 | 38 ± 8b | 21 ± 12 |
aResults are expressed as mean ± SD percentage of predicted values.
bP < .0001 compared with group 2.
Cardiopulmonary exercise tests in CF patients classified according to FEV
| FEV1 | | < 50% | ≥ 50% |
| VO2 peak, mL/kg/min | 25 ± 9 | 20 ± 5d | 30 ± 8.5 |
| VO2 peaka | 65 ± 21 | 51 ± 13d | 77 ± 20 |
| Borg dyspnea | 4.7 ± 1.9 | 5.6 ± 2b | 4.1 ± 1.5 |
| Borg Leg fatigue | 4.5 ± 1.8 | 5.2 ± 1.8b | 4.4 ± 1.7 |
| VE peak, L/min | 58 ± 22 | 44 ± 11d | 70 ± 21 |
| RR peak, min | 41 ± 9 | 43 ± 9b | 39 ± 8 |
| VT/FVC peak, % | 48 ± 11 | 47 ± 13 | 48.6 ± 8 |
| VE/VO2 peak | 41 ± 7 | 42 ± 7 | 41 ± 7 |
| VE/VCO2 peak | 36 ± 6 | 37 ± 6 | 35 ± 5 |
| BR, % | 24 ± 20 | 8 ± 11d | 37.5 ± 16 |
| VD/VT peak | 0.32 ± 0.11 | 0.39 ± 0.07d | 0.25 ± 0.10 |
| pH peak | 7.34 ± 0.04 | 7.34 ± 0.04 | 7.35 ± 0.04 |
| PaO2 peak, mm Hg | 76 ± 16 | 63 ± 10d | 89 ± 12 |
| PaCO2 peak, mm Hg | 40 ± 7 | 44 ± 6d | 36 ± 4 |
| P(A-a)O2 peak, mm Hg | 37 ± 13 | 46 ± 8d | 28 ± 10 |
| Lactatemia peak, mmol/L | 7 ± 2.6 | 6 ± 2d | 7.9 ± 3 |
| HR peaka | 82 ± 10 | 79 ± 8d | 86 ± 9 |
| VO2/HR peaka | 79 ± 22 | 67 ± 16d | 90 ± 21 |
aResults are expressed as mean ± SD percentage of predicted values.
bP < .01 compared with group 2.
cP < .001 compared with group 2.
dP < .0001 compared with group 2.
Correlation of clinical and functional variables with VO peak in CF patients
| Female | 102 | | .22 |
| ∆F508 homozygous mutation | 79 | | .02 |
| Exocrine pancreatic insufficiency | 102 | | .55 |
| | 99 | | .36 |
| Age, years | 102 | −0.11 | .29 |
| BMI, kg/m2* | 102 | 0.26 | .009 |
| Leukocytosis, 109/mm3 | 70 | −0.42 | .0003 |
| CRP, mg/L | 64 | −0.34 | .006 |
| Serum albumin, g/L | 43 | 0.34 | .02 |
| FEV1a* | 102 | 0.71 | < .0001 |
| FVCa* | 102 | 0.69 | < .0001 |
| RVa | 79 | −0.58 | < .0001 |
| DLCOa | 68 | 0.56 | < .0001 |
| PaO2, mm Hg | 98 | 0.43 | < .0001 |
| PaCO2, mm Hg | 98 | 0.11 | .29 |
| VE peak, L | 102 | 0.64 | < .0001 |
| VE/VCO2 peak* | 98 | −0.35 | < .0001 |
| BR, %* | 102 | 0.37 | .0001 |
| VD/VT peak* | 96 | −0.64 | < .0001 |
| PaCO2 peak, mm Hg* | 97 | −0.45 | < .0001 |
| P(A-a)O2 peak, mm Hg* | 97 | −0.54 | < .0001 |
| Lactatemia peak, mmol/L* | 86 | 0.59 | < .0001 |
| HR peaka | 102 | 0.40 | < .0001 |
aCorrelations based on percentage of predicted values.
*Selected variables for multivariate stepwise analysis.
Figure 1Correlation between VOpeak and FEV, FVC, VE/COpeak, BR, P(A-a)Opeak, and V/Vpeak in CF patients. VO2 peak, FEV1, FVC, and BR are expressed as percentage of predicted values. P(A-a)O2 peak is expressed as mm Hg.
Determinants of VO peak in CF patients
| FEV1 | 50 (0.84 [0.70;0.98])a | 31 (1.08 [0.70;1.45])a | 18 (0.67 [0.46;0.88])a |
| BR | 12 (−0.62 [−0.82;-0.42])a | 6 (−0.36 [−0.68;-0.04])b | 35 (−0.85 [−1.10;-0.59])a |
| VE/VCO2 peak | 5 (−1.13 [−1.56;-0.69])a | 15 (−0.95 [−1.41;-0.48])c | 6 (−1.52 [−2.22;-0.82])a |
Results are expressed as the partial r-square (r2), i.e. the percentage of VO2 alteration explained by the variable. Coefficient and 95% confidence intervals are shown between parentheses. FEV1, VE/VCO2 peak, and BR were independent predictors explaining 67% of exercise capacity (r2 = 0.67). In group 1, 31% of the VO2 peak was explained by FEV1, whereas, in group 2, BR was the major determinant explaining 35% of the VO2 peak.
Results are derived from multivariable analysis.
aAdjusted p value < .0001; bp = .027; cp = .0002.